Mc Sciences

Built from Survival. Driven by Science. Focused on Patients. MC Sciences is an emerging biotechnology company developing first-in-class superior therapeutics that target mast cells in several high-need diseases. The company’s scientific platform is built on the novel discovery of a unique mast cell receptor that controls the entire mast cell activity unlocking the potential for transformative treatments with superior efficacy and a strong safety profile. This scientific breakthrough enables the development of both small- and large-molecule therapeutics tailored to address specific unmet needs of several major disease areas in dermatology, respiratory, gastroenterology, fibrotic diseases, chronic inflammation disorders and neuroinflammation. 3 Key Factors That Differentiates MC Sciences 1) First-in-class based on novel discovered biology 2) Expected superior therapeutic profile with unique complete silencing selectively of mast cells contributing to the disease (closing majority of disease pathways) 3) In-human validated pharmacology and corresponding human ex-vivo validated with expected high probability for clinical success Therapeutic Potential in Major Disease Areas Therapeutic focus of MC Sciences are major diseases with high need as chronic urticaria, systemic mastocytosis, COPD, asthma, food allergy, pulmonary and liver fibrosis, and in addition chronic inflammation disorders, such as MCAS, fibromyalgia, IBS, long covid, chronic lyme, that are often driven by dysfunctional and chronically activated mast cells. Worldclass Leadership and Team Capabilities Founded by Prof. Gerhard J. Molderings and the CEO Wolfgang Taumann, MC Sciences is driven by a world-class team of leading drug development, science, and medical industry experts, and guided by board chairman Dr. Mikael Dolsten to advance MC Sciences towards clinics and patients. MC Sciences is headquartered in Germany, with operations in Naples, Florida, and backed by ROC Venture Group.